Soo‐Hwang Teo
A5034610853- BRCA gene mutations in cancer
- Genetic Associations and Epidemiology
- Nutrition, Genetics, and Disease
- Global Cancer Incidence and Screening
- Cancer Genomics and Diagnostics
- Ovarian cancer diagnosis and treatment
- Cancer Risks and Factors
- Cancer-related molecular mechanisms research
- Genomic variations and chromosomal abnormalities
- RNA modifications and cancer
- DNA Repair Mechanisms
- CRISPR and Genetic Engineering
- Genomics and Chromatin Dynamics
- Molecular Biology Techniques and Applications
- Genetics, Bioinformatics, and Biomedical Research
- RNA Research and Splicing
- Genetic factors in colorectal cancer
- Cancer-related Molecular Pathways
- Breast Cancer Treatment Studies
- Epigenetics and DNA Methylation
- Bioinformatics and Genomic Networks
- Digital Radiography and Breast Imaging
- AI in cancer detection
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
Cancer Research Malaysia
2016-2025
University of Malaya
2016-2025
University Malaya Medical Centre
2013-2024
Subang Jaya Medical Centre
2014-2024
University of Kuala Lumpur
2022-2024
University of Cambridge
1995-2024
University of Nottingham Malaysia Campus
2022
University of Wisconsin–Madison
2022
University of Manchester
2021
St Mary's Hospital
2021
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with 1,839 cancer), replication in an additional sample 2,646 carriers. We identified novel risk modifier locus at 1q32 for (rs2290854, P = 2.7×10−8, HR 1.14, 95% CI: 1.09–1.20). In addition, two loci: 17q21.31 (rs17631303, 1.4×10−8, 1.27, 1.17–1.38) 4q32.3 (rs4691139,...
The prevalence and spectrum of germline mutations in BRCA1 BRCA2 have been reported single populations, with the majority reports focused on White Europe North America. Consortium Investigators Modifiers BRCA1/2 (CIMBA) has assembled data 18,435 families 11,351 ascertained from 69 centers 49 countries six continents. This study comprehensively describes characteristics 1,650 unique 1,731 deleterious (disease-associated) identified CIMBA database. We observed substantial variation mutation...
Men with germline breast cancer 1, early onset (BRCA1) or 2, (BRCA2) gene mutations have a higher risk of developing prostate (PCa) than noncarriers. IMPACT (Identification genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) is an international consortium 62 centres 20 countries evaluating the use targeted PCa men mutations.
To provide precise age-specific risk estimates of cancers other than female breast and ovarian associated with pathogenic variants (PVs) in
Rare germline genetic variants in several genes are associated with increased breast cancer (BC) risk, but their precise contributions to different disease subtypes unclear. This information is relevant guidelines for gene panel testing and risk prediction.To characterize tumors BC susceptibility large-scale population- or hospital-based studies.The multicenter, international case-control analysis of the BRIDGES study included 42 680 patients 46 387 control participants, comprising women...
Background Cancer associated with smoking and drinking remains a serious health problem worldwide. The survival of patients is very poor due to the lack effective early biomarkers. FOXM1 overexpression linked majority human cancers but its mechanism unclear in head neck squamous cell carcinoma (HNSCC). Methodology/Principal Findings mRNA protein expressions were investigated four independent cohorts (total 75 patients) consisting normal, premalignant HNSCC tissues cells using quantitative...
HNF1B is overexpressed in clear cell epithelial ovarian cancer, and we observed epigenetic silencing serous leading us to hypothesize that variation this gene differentially associates with cancer risk according histological subtype. Here comprehensively map respect analyse DNA methylation expression profiles across subtypes. Different single-nucleotide polymorphisms associate invasive (rs7405776 odds ratio (OR)=1.13, P=3.1 × 10−10) (rs11651755 OR=0.77, P=1.6 10−8) cancer. Risk alleles for...
Abstract Treatment options for patients with brain metastases ( BMs ) have limited efficacy and the mortality rate is virtually 100%. Targeted therapy critically under‐utilized, our understanding of mechanisms underpinning metastatic outgrowth in limited. To address these deficiencies, we investigated genomic transcriptomic landscapes 36 from breast, lung, melanoma oesophageal cancers, using DNA copy‐number analysis exome‐ RNA ‐sequencing. The key findings were as follows. (a) Identification...
Polygenic risk scores (PRS) have been shown to predict breast cancer in European women, but their utility Asian women is unclear. Here we evaluate the best performing PRSs for European-ancestry using data from 17,262 cases and 17,695 controls of ancestry 13 case-control studies, 10,255 Chinese a prospective cohort (413 incident cancers). Compared middle quintile distribution, highest 1% PRS distribution ~2.7-fold lowest has ~0.4-fold developing cancer. There no evidence heterogeneity...
<h3>Background</h3> BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the Fanconi Anaemia Complementation (FANC) group family DNA repair proteins. Biallelic mutations in <i>BRIP1</i> are responsible for FANC J, and previous studies have also suggested that rare truncating variants associated with an increased risk breast cancer. These led to inclusion on targeted sequencing panels cancer prediction. <h3>Methods</h3> We evaluated a variant, p.Arg798Ter (rs137852986), 10...
<h3>Importance</h3> Increasing<i>BRCA1</i>and<i>BRCA2</i>(collectively termed herein as BRCA) gene testing is required to improve cancer management and prevent BRCA-related cancers. <h3>Objective</h3> To evaluate mainstream genetic using cancer-based criteria in patients with cancer. <h3>Design, Setting, Participants</h3> A quality improvement study cost-effectiveness analysis of different BRCA selection access procedures feasibility, acceptability, mutation detection performance was...
Abstract Molecular profiling of breast cancer has enabled the development more robust molecular prognostic signatures and therapeutic options for patients. However, non-Caucasian populations remain understudied. Here, we present mutational, transcriptional, copy number profiles 560 Malaysian tumours a comparative analysis cancers arising in Asian Caucasian women. Compared to women, show an increased prevalence HER2-enriched subtypes higher TP53 somatic mutations ER+ tumours. We also observe...
Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with increased breast cancer risk, but risks missense these genes uncertain. We analyzed data on 59,639 cases 53,165 controls from studies participating the Breast Cancer Association Consortium BRIDGES project. sampled training (80%) validation (20%) sets to analyze rare ATM (1146 variants), BRCA1 (644), BRCA2 (1425), CHEK2 (325), (472). evaluated according five silico prediction-of-deleteriousness algorithms,...